Epsilon Healthcare (ASX:EPN) ROA %: 11.64% (As of Dec. 2025)


What is Epsilon Healthcare ROA %?

Epsilon Healthcare ASX:EPN ROA % is 11.64% as of Dec. 2025. The stock has 4 warning signs investors should review. Among 1,006 Drug Manufacturers companies, Epsilon Healthcare ranks worse than 78.93% on this metric.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Epsilon Healthcare's annualized Net Income for the quarter that ended in Dec. 2025 was A$1.58 Mil. Epsilon Healthcare's average Total Assets over the quarter that ended in Dec. 2025 was A$13.58 Mil. Therefore, Epsilon Healthcare's annualized ROA % for the quarter that ended in Dec. 2025 was 11.64%.

The historical rank and industry rank for Epsilon Healthcare's ROA % or its related term are showing as below:

ASX:EPN' s ROA % Range Over the Past 10 Years
Min: -44.25   Med: -28.21   Max: -6.17
Current: -10.2

During the past 9 years, Epsilon Healthcare's highest ROA % was -6.17%. The lowest was -44.25%. And the median was -28.21%.

ASX:EPN's ROA % is ranked worse than
78.93% of 1006 companies
in the Drug Manufacturers industry
Industry Median: 2.685 vs ASX:EPN: -10.20

Epsilon Healthcare  (ASX:EPN) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Dec. 2025 )
=Net Income/Total Assets
=1.58/13.578
=(Net Income / Revenue)*(Revenue / Total Assets)
=(1.58 / 11.984)*(11.984 / 13.578)
=Net Margin %*Asset Turnover
=13.18 %*0.8826
=11.64 %

Note: The Net Income data used here is two times the semi-annual (Dec. 2025) net income data. The Revenue data used here is two times the semi-annual (Dec. 2025) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Epsilon Healthcare ROA % Related Terms


Epsilon Healthcare ROA % Historical Data

* Premium members only.

The historical data trend for Epsilon Healthcare's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Epsilon Healthcare ROA % Chart

Epsilon Healthcare Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROA %
Get a 7-Day Free Trial Premium Member Only -22.47 -44.25 -6.17 -44.19 -9.03

Epsilon Healthcare Semi-Annual Data
Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.64 -18.18 -58.53 -41.91 11.64

ASX:EPN vs ZTS: ROA % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Epsilon Healthcare's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Epsilon Healthcare ROA % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Epsilon Healthcare's ROA % distribution charts can be found below:

* The bar in red indicates where Epsilon Healthcare's ROA % falls into.



Epsilon Healthcare ROA % Calculation

Epsilon Healthcare's annualized ROA % for the fiscal year that ended in Dec. 2025 is calculated as:

ROA %=Net Income (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=-1.279/( (10.455+17.866)/ 2 )
=-1.279/14.1605
=-9.03 %

Epsilon Healthcare's annualized ROA % for the quarter that ended in Dec. 2025 is calculated as:

ROA %=Net Income (Q: Dec. 2025 )/( (Total Assets (Q: Jun. 2025 )+Total Assets (Q: Dec. 2025 ))/ count )
=1.58/( (9.29+17.866)/ 2 )
=1.58/13.578
=11.64 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is two times the semi-annual (Dec. 2025) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of 11.64% mean?
Epsilon Healthcare (ASX:EPN) has a ROA % of 11.64% as of Dec. 2025. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Epsilon Healthcare and its competitors. According to the industry distribution chart, Epsilon Healthcare ranks #794 out of 1006 companies in the Drug Manufacturers industry, placing it in the top 78.9%.
Is Epsilon Healthcare's ROA % too high?
Epsilon Healthcare's current ROA % is 11.64%. The Drug Manufacturers industry median ROA % is 2.69. Epsilon Healthcare's value of 11.64% is 333.5% above this industry median. Based on the distribution chart, Epsilon Healthcare ranks #794 out of 1006 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Epsilon Healthcare's ROA % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Epsilon Healthcare ranks #794 out of 1006 companies for ROA %. This places Epsilon Healthcare in the lower half of its industry. The industry median ROA % is 2.69. Epsilon Healthcare's value of 11.64% is 333.5% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Drug Manufacturers company?
The median ROA % among Drug Manufacturers companies is 2.69, based on 1,006 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Epsilon Healthcare's current ROA % of 11.64% is 333.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Epsilon Healthcare and its competitors. For the Drug Manufacturers industry, the median ROA % is 2.69 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Epsilon Healthcare's current ROA % is 11.64%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Epsilon Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Epsilon Healthcare (ASX:EPN) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.03, compared to a current price of A$0.02 — trading 26.7% below its estimated fair value. The current ROA % is 11.64% and 333.5% above the Drug Manufacturers industry median of 2.69. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Epsilon Healthcare (ASX:EPN), the current ROA % is 11.64% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Epsilon Healthcare Business Description

Address 5 Goodyear Street, Southport, QLD, AUS, 4215
Epsilon Healthcare Ltd is an Australian based, globally active healthcare organisation. It operates a diversified and vertically integrated portfolio of assets, including healthcare and clinics operation, pharmaceutical contract development and manufacturing operation & pharmacy services. The company offers end-to-end solutions across the healthcare spectrum: from product development and manufacturing to patient care. The company's three (3) main operating segments are: a. Contract Development and Manufacturing activities, b. Telehealth medical practice services; and c. Pharmacy services. The majority of revenue is derived from the Contract Development and Manufacturing activities segment.